Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.45 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 4/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PRKCG | P05129 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2374130 | 0.80 | PPID (0.47) | PPIDGPR142ROCK2ROCK1CYP3A4 | |
| SCHEMBL2374561 | 0.74 | PPID (0.48) | PPIDGPR142ROCK2ROCK1CYP3A4 | |
| SCHEMBL2374570 | 0.74 | PPID (0.48) | PPIDGPR142ROCK2ROCK1CYP3A4 | |
| SCHEMBL1931193 | 0.73 | MMP8 (0.56) | PPID | |
| SCHEMBL13915549 | 0.73 | MMP8 (0.56) | PPID | |
| SCHEMBL28699378 | 0.71 | BACE1 (0.54) | TSHR | |
| SCHEMBL29176945 | 0.71 | ALDH1A1 (0.50) | CYP2D6HDAC1MAPK1 | |
| SCHEMBL2376148 | 0.70 | PPID (0.41) | PPIDGPR142ROCK2ROCK1CYP3A4 | |
| SCHEMBL29788300 | 0.70 | MAPT (0.49) | PPIDCYP3A4MAPK1TSHR | |
| SCHEMBL2374193 | 0.70 | PPID (0.42) | PPIDGPR142ROCK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224210-A1 | NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS | CTSA, BECN1, HDAC6 | PPID 654/4885NLRP3 1203/4885GPR142 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.